Literature DB >> 17634476

Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?

Willem J van Heeckeren, Jose Ortiz, Matthew M Cooney, Scot C Remick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17634476     DOI： 10.1200/JCO.2007.11.5113

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  29 in total

Review 1.  Targeting angiogenesis in gynecologic cancers.

Authors:  Behrouz Zand; Robert L Coleman; Anil K Sood
Journal:  Hematol Oncol Clin North Am       Date:  2012-06       Impact factor: 3.722

Review 2.  Adverse effects of anticancer agents that target the VEGF pathway.

Authors:  Helen X Chen; Jessica N Cleck
Journal:  Nat Rev Clin Oncol       Date:  2009-07-07       Impact factor: 66.675

3.  Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib.

Authors:  Tasuku Nagasawa; Md Abdul Hye Khan; John D Imig
Journal:  Clin Exp Pharmacol Physiol       Date:  2012-05       Impact factor: 2.557

4.  A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.

Authors:  Geoffrey I Shapiro; Stewart McCallum; Laurel M Adams; Laurie Sherman; Steve Weller; Suzanne Swann; Harold Keer; Dale Miles; Thomas Müller; Patricia Lorusso
Journal:  Invest New Drugs       Date:  2012-10-06       Impact factor: 3.850

Review 5.  Off-tumor target--beneficial site for antiangiogenic cancer therapy?

Authors:  Yihai Cao
Journal:  Nat Rev Clin Oncol       Date:  2010-08-03       Impact factor: 66.675

6.  Targeting prion-like protein doppel selectively suppresses tumor angiogenesis.

Authors:  Taslim A Al-Hilal; Seung Woo Chung; Jeong Uk Choi; Farzana Alam; Jooho Park; Seong Who Kim; Sang Yoon Kim; Fakhrul Ahsan; In-San Kim; Youngro Byun
Journal:  J Clin Invest       Date:  2016-03-07       Impact factor: 14.808

7.  Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.

Authors:  Michael L Maitland; Kristen E Kasza; Theodore Karrison; Kristin Moshier; Laura Sit; Henry R Black; Samir D Undevia; Walter M Stadler; William J Elliott; Mark J Ratain
Journal:  Clin Cancer Res       Date:  2009-09-22       Impact factor: 12.531

8.  Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.

Authors:  Suzanne E Dahlberg; Alan B Sandler; Julie R Brahmer; Joan H Schiller; David H Johnson
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544

9.  Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.

Authors:  Michael L Maitland; George L Bakris; Henry R Black; Helen X Chen; Jean-Bernard Durand; William J Elliott; S Percy Ivy; Carl V Leier; Joann Lindenfeld; Glenn Liu; Scot C Remick; Richard Steingart; W H Wilson Tang
Journal:  J Natl Cancer Inst       Date:  2010-03-29       Impact factor: 13.506

10.  Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.

Authors:  D A Reardon; A Desjardins; J J Vredenburgh; S Gururangan; J H Sampson; S Sathornsumetee; R E McLendon; J E Herndon; J E Marcello; J Norfleet; A H Friedman; D D Bigner; H S Friedman
Journal:  Br J Cancer       Date:  2009-11-17       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.